Biofarm (BSE:BIO) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSE:BIO Biofarm SA BSE:BIO
69 GF Score
Price lei1.35
GF Value lei0.87
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Biofarm Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Biofarm Valuation Rank Related Terms

BSE:BIO
69GF Score
Biofarm SA BSE:BIO
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Biofarm (BSE:BIO) Overvalued in 2026?

Based on GuruFocus' analysis, Biofarm stock appears to be overvalued. The current stock price of lei1.35 is trading 54.6% above its estimated GF Value™ of lei0.87. GuruFocus considers Biofarm to be Significantly Overvalued.

Key valuation signals for BSE:BIO:

  • Valuation Rank:
  • GF Value™: lei0.87 vs. price of lei1.35 (54.6% above fair value)
  • GF Score™: 69/100 with 5 warning signs

No single metric tells the full story. See the BSE:BIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biofarm Business Description

Address 99 Logofatul Tautu Street, Sector 3, Bucharest, ROU, 031212
Biofarm SA is a company engaged in production and marketing in the pharmaceutical sector. It is involved in the manufacture and wholesale of over-the-counter drugs, prescription medications, and dietary supplements. The firm's product portfolio includes pharmaceutical preparations for the digestive system, musculoskeletal system, immune stimulation, respiratory system, cold & flu symptoms, and venous circulation improvement, as well as multivitamins, antioxidants, antiseptics, disinfectants, and cosmetics, among others. Some of its brands are Triferment, Colebil, Cavit, Anghirol, Clorocalcin, and Bixtonim. Additionally, the company offers services, such as investment in research, promotion, and packaging.
69GF Score

Get the complete analysis for BSE:BIO

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

lei1.35
Price
lei0.87
GF Value